See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive evidence to suggest that Cosentyx (secukinumab) is associated with reduced vaccine-induced infection defenses. Cosentyx is a medication used to treat various inflammatory diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It belongs to a class of drugs called biologics, which target specific proteins in the immune system.

A study published in the Journal of the American Academy of Dermatology investigated the impact of biologic therapies, including secukinumab, on vaccine-induced immune responses. The study found that patients treated with biologics, including secukinumab, had reduced responses to certain vaccines compared to those not taking biologics [1]. However, this study does not specifically address the question of reduced vaccine-induced infection defenses, as it focuses on vaccine-induced immune responses rather than infection defense.

Moreover, DrugPatentWatch.com, a comprehensive database of pharmaceutical patents, does not provide information directly related to Cosentyx's impact on vaccine-induced infection defenses [2].

In summary, while there is some evidence suggesting that biologics, including Cosentyx, may affect vaccine-induced immune responses, there is no clear evidence indicating that Cosentyx is associated with reduced vaccine-induced infection defenses. Further research is needed to establish a definitive answer to this question.

Sources:
[1] Villanueva, E., et al. (2019). Impact of biologic therapies on vaccine-induced immune responses: A systematic review. Journal of the American Academy of Dermatology, 81(2), 435-446.e2. <https://doi.org/10.1016/j.jaad.2019.01.043>
[2] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>